Aduhelm Approval Prompts Discussions on Reforming the FDA’s Accelerated Approval Pathway
The Food and Drug Administration (FDA)’s contentious approval of Biogen’s Aduhelm has prompted discussions on how the accelerated approval process [...]
Cost-Effective Insulin Glargine Biosimilar Could Upend Reference Diabetes Drug; McKinsey Estimates Biosimilar Market Will Hit $30 Billion by 2025
The Food and Drug Administration (FDA) recently approved Semglee, an insulin glargine biosimilar product. Compared to reference drug Lantus, the [...]
On-Demand Webinar Highlights the Evolving Roles of RWD and AI in Successful Drug Launches
An on-demand webinar features insight from data experts at Amazon Web Services (AWS), Infosys, and Genmab regarding drug launches. Analytics, [...]
COVID-19 Pandemic Brings to Light Record Pharma Profits and Promotes Discussions on Global Intellectual Property Agreements
As the COVID-19 pandemic continues, pharmaceutical companies report revenue in the billions. Co-Founder of the Initiative for Medicines, Access & [...]
Biden’s Prescription Drug Pricing Approach Pushes for Value-Based Pricing
President Joe Biden’s plan for lowering drug prices includes tying a drug’s price to its therapeutic value, according to recent [...]
Researchers Claim Drug Price Limits Won’t Impact Innovation, PhRMA Strongly Disagrees
In a recently published article, researchers at Bentley University and West Health conclude that limiting drug prices will not affect [...]
Should the FDA Follow Advisory Committee Votes in Drug Approvals?
A recent survey requested feedback from advisory committee members. Most respondents thought that a thumbs down from committee members should [...]
AIS Health’s RADAR on Drug Benefits Article Highlights Possible PBM Disruptor DomaniRx
AIS Health’s RADAR on Drug Benefits released an article on DomaniRx, a cloud-based pharmacy benefit manager (PBM) platform. The emerging [...]
NICE’s Accelerated Drug Approval Process Aims to Overcome COVID-19 Delays
The UK’s National Institute for Health and Care Excellence (NICE) has announced an accelerated approval process that is intended to [...]
Brown University Biostatistician Discusses Intercurrent Events, RWE, and Estimands
Dr. Roee Gutman recently shared his thoughts on the state of real world evidence (RWE) as it relates to health [...]
Register Today for Upcoming MAPS Launch Excellence MasterClass Featuring Industry Leaders in Medical Affairs
The Medical Affairs Professional Society (MAPS) will host a Launch Excellence MasterClass on October 4th and 5th in New York [...]
National Academy of Sciences, Engineering and Medicine Released Pro-Pharma Report on $750 Million in Yearly Prescription Drug Waste Following Undisclosed Pharma Donations
Congress tasked the National Academy of Sciences, Engineering and Medicine with providing an impartial view of the $750 million in [...]
95 Pharma-Backed Oncologists Support Woodcock for FDA Commissioner
Dr. Janet Woodcock has faced widespread criticism as news spread that she was being considered for Food and Drug Administration [...]
Understanding the Impact of COVID-19 on Pharma Market Trends and Costs
The COVID-19 pandemic is bringing about major changes to the healthcare and pharma industries. Managing Director of BioPharma Futures Mel [...]
Philip Morris Acquires Several Companies, Details Beyond Nicotine Project in Brand Overhaul
Philip Morris International Inc. recently acquired OtiTopic, Vectura, and Fertin Pharma A/S. The acquired companies offer pharmaceutical products for heart [...]
BCG Market Access Roundtable Article Highlights Healthcare and Pharma Trends Including RWD, Digital Tools, and Healthcare Policy Changes
The Boston Consulting Group (BCG) Market Access Roundtable shared updates to its key trends first released half a decade ago. [...]
Managed Entry Agreements Could Bring Affordability to Multibillion-Dollar Novel Gene Therapy Market
Cogentia’s Senior Analyst Mark Orchard discusses how managed entry agreements (MEAs) could become a major trend in improving access to [...]
Bristol Myers Squibb Senior VP Discusses Career Journey, Leadership Style, and Improving Access to Drugs Globally
Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, discusses her career path and evolving [...]
New Article Details $93.3 Billion Annual Costs in Drug Utilization Management
An article published in Health Affairs details the multibillion-dollar costs associated with inflated drug utilization management. The estimated $93.3 billion [...]
ICER President Discusses How Iffy Biogen Decision May Bring Down FDA’s Accelerated Approval Program
Steve Pearson of the Institute for Clinical and Economic Review (ICER) weighed in on how the Food and Drug Administration’s [...]
MMIT’s AIS Health Article Details Efficacy and Costs of Specialty Drugs
MMIT’s AIS Health recently published an article on specialty pharmacy. Employers are typically resistant to drugs commanding high price tags. [...]
Pfizer and BioNTech Raise Price of COVID-19 Vaccine as UK Orders Booster Shots, Pfizer’s 2021 Sales Hit $11.3 Billion
Pfizer and BioNTech announced a price increase for COVID-19 booster shots—from £18 to £22. The European Union and the United [...]
Novartis and University of California-Berkeley Researchers Estimate $93 Billion Wasted Yearly Across Healthcare Stakeholders, Propose Value-Based Pricing System
Researchers at the University of California-Berkeley and Novartis note that $93 billion is wasted yearly in addressing healthcare utilization management, [...]
NPC and CEVR Researchers Find That Patient Voices Are Missing in Discussions on Drug Coverage
Researchers at the National Pharmaceutical Council (NPC) and the Center for the Evaluation of Value and Risk in Health (CEVR) [...]
PhRMA President and CEO Discusses Lowering Prescription Drug Prices Using Patient-Centered Medicare Legislation
PhRMA CEO and President Stephen Ubl discusses how new Medicare legislation could impact consumers at a time when patients continue [...]